Worldwide Market for In Vitro Diagnostic (IVD) Tests, 6th Edition [with 2009 economy preface], The

Get more info on this report!

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 6th Edition [with 2009
economy preface]

December 1, 2008

This edition of Kalorama’s comprehensive and indispensable report covers the breadth
of traditional IVD testing. The report contains complete market statistics and analysis for
all areas of IVD, including:

• Point-of-Care
• Core Lab
• Immunoassays
• Molecular Assays
• Hematology
• Coagulation
• Microbiology and Virology
• Blood Banking
• Histology and Cytology

Market size, growth, share, and geographic distribution, as well as trends in technology
development, regulatory and reimbursement issues, clinical care, and business
environments are discussed. Projections are made through 2012.

Six Times Kalorama Has Examined the IVD Market in Full

This 900-page edition greatly expands coverage of the field and tracks the most
important developments. Expanded or added in this edition are sections on:

• The status of POC and decentralization in lab medicine
• Miniaturization and molecularization of devices
• Geo-economic and demographic influences on markets
• Non-invasive sampling
• Greatly expanded market data on PGx and SNP testing
• Revamped segmentation for clinical chemistry to include workstations and
immunoanalyzers
• More information about more immunoassays

• Focus on the renewed interest in microbiology/virology based on
resistance and the re-emergence of serious hospital- and community-
based organisms
• World blood banking developments
• Expanded sections on histology/cytology developments including
emerging areas such as tissue microarrays, circulating tumor cells, and
genomics-fueled innovation.

In addition, there are now profiles of established and emerging players in IVD, more
than 276 companies, from the top tier to emerging and niche competitors to watch.

As part of its coverage, the report breaks down the IVD market for the following regions.

• North America
• Europe (EU)
• Eastern Europe
• South America
• Asia (China and India as subsegments)
• Rest of World

A Report Designed for a Changing Industry

In this sixth edition of The Worldwide Market for In Vitro Diagnostic Tests Kalorama
Information has reorganized the presentation of the IVD market in a manner that better
reflects how the industry has evolved since the first edition was published in 1997. At
that time, molecular testing was a small emerging discipline that related to chlamydia,
gonorrhea, TB, and some inherited diseases.

That first edition didn’t even have a chapter for molecular diagnostics; it was a
miscellaneous. Now, molecular tests are common in several segments - infectious
diseases, bacterial identification, coagulopathologies, blood unit screening, histology
and soon as POC devices. Therefore the molecular chapter in this report presents
technology and market issues that are common to all segments and concentrates on
purely molecular tests for inherited diseases. Molecular tests used in other segments
are included in the appropriate chapter. In 1997, POC testing meant glucose testing.

Similar to molecular testing, rapid and POC tests are becoming an important part of
testing on all fronts. Here too the POC chapter presents technology and market issues
that are common to all segments and concentrates on blood glucose monitoring.

A Note About The Economy in 2009 and our Forecasts

This report was completed in 2008 before the economic meltdown of 2008/2009 was
fully apparent. The report estimates the world market for IVD products. Kalorama
Information anticipates that this estimate holds true in spite of the current
financial situation. There are many reasons for this rationale. In vitro diagnostics were

the first products targeted for cutbacks in the major markets, the IVD industry did not
experience the explosive growth seen in some medical devices, purchases are through
group purchasing organization, new healthcare initiatives proposed by the new U.S.
administration under the guidance of President Barack Obama further bolster the use of
IVDs, and demand for healthcare and thus diagnostic tests in all the major markets. A
special appendix to this report is included to address the economy

Table of Contents

Chapter one: Executive Summary

• Overview
• Size and Growth of the Market
o Important Changes in the IVD Market
o IVD Growth in Developed Countries
o Privatization of Healthcare
o Newly Aggressive Foundations and Initiatives

• Positive and Negative Market Trends
o Human Genome Project Applications
o Remote Patient Monitoring
o Demand for Data
o The Informed Medical Consumer
o Price Point of New Products
o Focus On Home Care Raises Questions

• Top Suppliers and Niche Players
• Scope and Methodology
o Exchange Rates
o Scope
o Methodology

Chapter two: Introduction

• New Report Design
• Lab Medicine Disciplines and Applications
o Core Lab

• Market Analysis of IVD Market Segments
• Age of the Giants and Smaller Colossuses

• Licenses and Distribution Agreements
• Top Suppliers and Niche Players
• Point of View

Chapter three: Overview of Global In Vitro Diagnostic Markets

• The Boomers and Aging Worldwide
• Healthcare Spending Worldwide
• World Segments of the IVD Market and IVD Market Evolution
o The United States
o Japan—Just Barely Holding Its Own
o Europe
o China
o India
o Africa

CHAPTER FOUR: TRENDS AND INNOVATIONS:

• Background
• Diabetes innovation
• Miniaturization And Chip Progress
• Non-Invasive Techniques And Alternative Samples
• Commercialization Issues : Patents and market innovation
• Direct to Consumer marketing
• Patient Management and Outcomes-Based Medicine
• Economics of New Tests and Technologies - the old don't disappear
• Post Genomics and Pharmacogenomics - reality check
• Growing Globalization of Public Health Crises - SARS, West Nile, Biowar impact
• Regulatory and Reimbursement Issues And Novel Devices

CHAPTER FIVE: Point-of-Care Tests

• Overview
• Special Topics
o POC in world market
o The pros and cons of POC testing
o Telemedicine Goes Wireless

• Market Analysis
o Blood Glucose Monitoring

• The Commercial Outlook for POC Tests

• Companies to Watch

chapter six: The Core Lab

• Core Lab Overview
• Overview of Chemistry Tests
• Special Topics
o Competing for Customer Loyalty
o Client Side
o Vendor Side
o Managed Service Plans

• Market Analysis
o Lab-based Chemistries
o Critical Care Chemistries
o Responses to Cost Pressures

• The Commercial Outlook for Chemistry Tests
• Abaxis, Inc.
o Recent Revenue History
o Key Comment
o Details

• Abbott Diagnostics
o Key Comment
o Details

• Beckman Coulter Inc.
• Beckman Coulter Inc.
o Key Comment
o Details

• Instrumentation Laboratory (IL)

o Key Comment
o Details

• IRIS International, Inc.
• IRIS International, Inc.
o Key Comment
o Details

• Maxmat S.A.
• Maxmat S.A.
o Key Comment
o Details

• Nova Biomedical
o Key Comment
o Details

• Olympus America Inc.
o Key Comment
o Details

• OPTI Medical Systems, Inc.
• OPTI Medical Systems, Inc.
o Key Comment
o Details

• Ortho Clinical Diagnostics (OCD)

o Key Comment
o Details

• Probe Scientific
o Key Comment
o Details

• Radiometer A/S
o Key Comment
o Details

• Randox Laboratories
o Key Comment
o Details

• Roche Diagnostics
o Key Comment
o Details

• Siemens Medical Solutions Diagnostics
o Key Comment

• Sphere Medical Ltd.
o Key Comment
o Details

chapter seven: Immunoassays

• Overview of Immunoassays
o New Immunoassays
o Changes in the Immunoassay Market

• Special Topics
o Proteins: How Low Can You Go
o New Platforms
o immunoPCR
o FACTT
o NADIA
o ELISA
o Role of Immunoassays in Disease Management

• Market Analysis: Leading Suppliers and Growth Potential
o Regional Breakdown
o Abbott
o Roche
o Beckman Coulter
o Siemens/Bayer
o bioMerieux
o Seimens/Dade Behring

• Immunoassay Test Segments— Mature, Maturing and Emerging
o Thyroid Function
o Therapeutic drug tests
o IMx Sirolimus
o Tacrolimus
o Mature Immunoassays
o Anemia
o Fertility
o Tox/DAU
o Allergy
o Maturing Immunoassays
o Proteins
o Growth Immunoassays
o Tumor Markers
o Cardiac Markers
o Autoimmune
o Sepsis
o Diabetes

o Miscellaneous

• Point-of-care OTC and Professional Use
o Patient Self-tests (OTC)
o Pregnancy
o Fecal Occult Blood
o Breath Tests
o Professional POC
o Cholesterol
o Cardiac Markers
o Cancer Markers

• The Commercial Outlook for Immunoassays
• Aesku Diagnostics
o Key Comment
o Details

• AspenBio Pharma, Inc.
o Key Comment
o Details

• Axela Biosensors, Inc.
o Key Comment
o Details

• Axis-Shield plc
o Key Comment
o Details

• BG Medicine Inc.
o Key Comment
o Details

• The Binding Site
o Key Comment
o Details

• Biocheck Inc.
o Key Comment
o Details

• BioCurex, Inc.
o Key Comment
o Details

• BioMarker Group
o Key Comment
o Details

• BioMedical Diagnostics SA (BMD)
o Key Comment
o Details

• Biosite Incorporated
o Key Comment
o Details

• BioSystems International
o Key Comment
o Details

• Bio-Rad Laboratories Inc.
o Key Comment
o Details

• Chimera Biotec GmbH
o Key Comment
o Details

• China Medical Technologies, Inc.
o Key Comment
o Details

• Concateno Plc
o Key Comment
o Details

• Conceivex, Inc.
o Key Comment
o Details

• Corgenix Medical Corporation
o Key Comment

o Details

• Crescent Diagnostics Ltd.
o Key Comment
o Details

• Critical Therapeutics, Inc.
o Key Comment
o Details

• Cylex Incorporated
o Key Comment
o Details

• CytoCore, Inc.
o Key Comment
o Details

• Diazyme Laboratories
o Key Comment
o Details

• Early Detect, Inc.
o Key Comment
o Details

• ESA Biosciences Inc.
o Key Comment
o Details

• Euroimmun AG
o Key Comment
o Details

• Fujirebio Diagnostics. Inc. (FDI)
o Key Comment
o Details

• Genosis Inc.
o Key Comment
o Details

• Grifols, S.A.
o Key Comment
o Details

• Guava Technologies, Inc.
o Key Comment
o Details

• INOVA Diagnostics Inc.
o Key Comment
o Details

• LifeAssays AB
o Key Comment
o Details

• Matritech
o Key Comment
o Details

• Medical Services International Inc.
o Key Comment
o Details

• Meridian Bioscience, Inc.
o Key Comment
o Details

• Miraculins Inc.
o Key Comment
o Details

• Nanobac Pharmaceuticals Inc.
o Key Comment
o Details

• Nanogen

o Key Comment
o Details

• Onconome, Inc.
• Onconome, Inc.
o Key Comment
o Details

• Panacea Pharmaceuticals, Inc.
o Key Comment
o Details

• Phadia AB
o Key Comment
o Details

• Pria Diagnostics LLC
o Key Comment
o Details

• Pronostics Ltd.
o Key Comment
o Details

• Qualigen, Inc.
o Key Comment
o Details

• Quidel Corporation
o Key Comment
o Details

• Reagena Ltd.
o Key Comment
o Details

• Response Biomedical Corporation
o Key Comment
o Details

• Serion Immundiagnostica GmbH
o Key Comment
o Details

• Singulex Inc.
o Key Comment
o Details

• Spectral Diagnostics Inc.
o Key Comment
o Details

• Synova Healthcare, Inc.

o Key Comment
o Details

• TOSOH Corporation
o Key Comment
o Details

chapter eight: Molecular Assays

• Overview
• Special Topics
o The Special Case of Regulating Molecular Tests

• The promise of personalized medicine
• PCR Patent Update
• Molecular Testing Innovation: Technology and Players
• Market Analysis
o Nucleic Acid Tests
o Prenatal Chromosome Analysis
o Tissue Typing

• The Commercial Outlook for Molecular Tests
• 23andMe, Inc.
o Recent Revenue History:
o Key comment:
o Details

• 454 Life Sciences Corporation
• 454 Life Sciences Corporation
o Key Comment:
o Details
o Affymetrix

o Key Comment:
o Details

• Almac Diagnostics
o Key Comment:
o Details

• Althea Technologies, Inc.
o Key Comment:
o Details

• Arcxis Biotechnologies
o Key Comment:
o Details

• Asuragen, Inc.
o Key Comment:
o Details

• AutoGenomics, Inc.
o Key Comment:
o Details

• BioNanomatrix
o Key Comment:
o Details

• Bruker BioSciences Corporation
o Key Comment:
o Details

• Celera
o Key Comment:
o Details

• CeMines, Inc.
o Key Comment:
o Details

• Clinical Data, Inc.
o Key Comment:
o Details

• CombiMatrix Molecular Diagnostics (CMDX)
o Key Comment:
o Details

• Consumer Genetics
o Key Comment:
o Details

• Curidium Medica Plc

o Key Comment:
o Details

• Sekisui Medical Co., Ltd
o Key Comment:
o Details

• deCode Genetics Inc.
o Key Comment:
o Details

• diaDexus Inc.
o Key Comment:
o Details

• DiagnoCure
o Key Comment:
o Details

• DxS
o Recent Revenue history:
o Key Comment:
o Details

• eGene Inc.
o Key Comment:
o Details

• Eiken Chemical Co., Ltd
o Key Comment:
o Details

• Epigenomics AG
o Key Comment:
o Details

• EXACT Sciences Corporation
o Key Comment:
o Details

• Exiqon A/S
o Key Comment:
o Details

• Fluidigm Corporation
o Key Comment:
o Details

• Gen-Probe Inc.
o Key Comment:
o Details

• Genomic Health
o Key Comment:
o Details

• Genzyme Corporation
o Key Comment:
o Details

• Greiner Bio-One International AG
o Key Comment:
o Details

• Ipsogen
o Key Comment:
o Details

• Laboratory Corporation of America Holdings (LabCorp)
o Key Comment:
o Details

• Luminex Corporation
o Key Comment:
o Details

• MacroArray Technologies, LLC
o Key Comment:
o Details

• Med BioGene, Inc. (MBI)

o Key Comment:
o Details

• Modern Technology Corp.
o Key comment:
o Details

• Myriad Genetics, Inc.
o Key Comment:
o Details

• Nanosphere, Inc.
o Key Comment:

• Navigenics
o Recent revenue History:
o Key Comment:
o Details

• NeuroMark
o Key Comment:
o Details

• NorDiag ASA
o Key Comment:
o Details

• Novartis Vaccines and Diagnostics/Chiron
o Key Comment:
o Details

• Nuvera Biosciences
o Key Comment:
o Details

• Orion Genomics
o Key Comment:
o Details

• Osmetech plc
o Key Comment:
o Details

• ParagonDx LLC
o Key Comment:
o Details

• PerkinElmer, Inc.
o Key Comment:
o Details

• Power3 Medical Products, Inc.
o Key Comment:
o Details

• Progenika Biopharma
o Key Comment:
o Details

• Provista Diagnostics
o Key Comment:
o Details

• Psynomics Incorporated
o Key Comment:
o Details

• Q Chip Ltd.
o Key Comment:
o Details

• Qiagen N.V.
o Key Comment:
o Details

• Quest Diagnostics Incorporated
o Key Comment
o Details

• Rosetta Genomics Ltd.

o Key Comment:
o Details

• Seegene, Inc.
o Key Comment:
o Details

• SensiGen LLC
o Key Comment:
o Details

• Sequenom, Inc.
o Key Comment:
o Details

• Source MDx
o Key Comment:
o Details

• Tepnel Diagnostics Ltd.
o Key Comment
o Details

• Third Wave Technologies Inc.
o Key Comment:
o Details

• Whatman plc
o Key Comment
o Details

• Xenomics, Inc.
o Key Comment:
o Details

chapter nine: Hematology

• Overview
• Decentralized Hematology Testing
• Market Analysis: Leading Suppliers
• The Commercial Outlook for Hematology Tests
• Alifax S.p.a.
o Key Comment
o Details

• CellaVision AB
o Key Comment
o Details

• Chempaq A/S
o Key Comment
o Details

• Diesse Diagnostica Senese S.p.A.
o Key Comment
o Details

• ELITech Group
o Key Comment
o Details

• Horiba ABX S.A.
o Key Comment
o Details

• QBC Diagnostics, Inc.
o Key Comment
o Details

• Sysmex Corporation
o Key Comment
o Details

chapter TEN: Coagulation

• Overview of Coagulation and Immunohematology Tests
• Market Analysis
o Lab-Based Testing
o D-dimer
o Aspirin Insensitivity
o Genetic Markers of Hypercoagulopathies
o Factor V
o Warfarin
o Decentralized Coagulation Testing - Professional Use
o Decentralized Coagulation Testing - OTC
o Leading Suppliers

• The Commercial Market for Coagulation Tests
• HemoSense, Inc.
o Recent Revenue History: 2007 $31.9 million (est)

o Key Comment
o Details

• International Technidyne Corp (ITC)
o Key Comment
o Details

• Diagnostica Stago
o Key Comment
o Details

• Trinity Biotech plc
o Revenues

• Revenues
o Key Comment
o Details

• ZyCare, Inc.
o Key Comment
o Details

chapter eleven: Microbiology and Virology

• Overview
• Special Topics
o Hospital Acquired Infections (HAIs)
o MRSA
o HIV, a 25-year Phenomenon
o Rapid Tests for HIV
o Tuberculosis
o Cellestis
o MDR-TB

o Emerging Organisms and the Globalization of Infectious Diseases
o SARS
o Viral Hemorrhagic Fever
o Dengue
o MPV
o Globalization Brings New Threats
o Yaws
o Andenovirus type 14
o Non-Traditional Systems
o FISH
o Cell Counting by Flow Cytometry
o Laser Based Microbial Detection

• Market Analysis
o Supplies
o Microbial Identification and Antimicrobial Sensitivity Tests
o Blood Culture
o Rapid Tests
o Immunoassays - Lab based
o STDs
o Flu
o Immunoassays - Rapid
o Molecular Tests

• The Commercial Outlook for Microbiology / Virology Tests
• 3M Medical Diagnostics
o Key Comment
o Details

• Accelr8 Technology Corporation
o Key Comment
o Details

• AdvanDx, Inc.

o Key Comment
o Details

• Becton, Dickinson and Company (BD)
o Key Comment
o Details

• bioMérieux Inc.
o Key Comment
o Details

• bioLytical Laboratories
o Key Comment
o Details
o Key Comment
o Details

• The BioPen Company
o Key Comment
o Details

• Calypte Biomedical Corporation
o Key Comment
o Details

• Cellestis Ltd
o Key Comment

o Details

• Cepheid
o Key Comment
o Details

• Chembio Diagnostics, Inc.
o Key Comment
o Details

• Common Sense Ltd.
o Key Comment
o Details

• Diagnostic HYBRIDS, Inc. (DHI)
o Key Comment
o Details

• Dynacon Inc.
o Ket Comment:
o Details

• Enigma Diagnostics Limited
o Key Comment
o Details

• GenPrime, Inc.
o Key Comment
o Details

• Hain Lifescience GmbH
o Key Comment
o Details

• HIVmirror LLC
o Key Comment
o Details
o Key Comment
o Details

• MedMira, Inc.
o Key Comment
o Details

• Microbionetics/IME, Inc.
o Key Comment
o Details

• Micro Imaging Technology, Inc. (MIT)
o Key Comment
o Details

• Microgen Bioproducts Ltd.

o Key Comment
o Details

• Mobidiag Oy
o Key Comment
o Details

• Molzym GmbH & Co. KG
o Key Comment
o Details

• Monogram Biosciences, Inc.
o Key Comment
o Details

• Myconostica, Ltd.
o Key Comment
o Details

• OraSure Technologies, Inc.
o Key Comment
o Details

• Oxoid
o Key Comment
o Details

• Pathway Diagnostics Corporation
o Key Comment
o Details

• Pocared Diagnostics Ltd
o Key Comment
o Details

• SIRS-Lab
o Key Comment
o Details

• StatSure Diagnostic Systems, Inc.
o Key Comment
o Details

• TREK Diagnostic Systems
o Key Comment
o Details

chapter twelve: Blood Banking Services

• Overview
o Donor Pools, Costs, Safety, Blood Supply

• The Safety Imperative
o Chagas
o West Nile
o Hepatitis and HIV

o Platelets

• Market Analysis
o Blood Grouping
o Immunoassays
o Nucleic Acid Testing (NAT) Continues to Grow

• The Commercial Outlook for Blood Banking
• Cerus Corporation
o Key Comment:
o Details

• Navigant Biotechnologies, LLC
o Key Comment:
o Details

• Haemonetics Corporation
o Key Comment:
o Details

• Immucor, Inc.
o Key Comment:
o Details

• Medion Diagnostics AG
o Recent Revenue History: Private
o Key Comment:
o Details

• Pall Corporation
o Key Comment:
o Details

• Sanquin Reagents
o Key Comment
o Verax Biomedica Inc.
Recent Revenue History
Private
Key Comment
Details

chapter thirteen: Histology and Cytology

• Overview
• Special Topics
o Cancer Drives Histology/Cytology Development
o The Future of the Pap Smear & HPV testing

• Market Analysis
o Histology/Cytology
o Traditional Stains
o In situ Hybridization Products: ISH, CISH and FISH
o Immunohistochemistry and in situ Hybridization
o Flow Cytometry

• The Commercial Outlook for Histology and Cytology Tests
• Agendia B.V.
o Key Comment
o Details

• Aperio Technologies, Inc.

o Private
o Key Comment
o Details

• Applied Imaging Corp./Genetix
o Key Comment
o Details

• AviaraDx (formerly Arcturus Biosciences)
o Key Comment
o Details

• BioImagene, Inc.
o Key Comment
o Details

• BIOVIEW, Inc.
o Key Comment
o Details

• Celerus Diagnostics
o Key Comment
o Details

• Clarient Inc. (formerly ChromaVision)
o Key Comment
o Details

• Compucyte Corporation
o Key Comment
o Details

• Cytyc Corporation
o Key Comment
o Details

• Dako A/S
o Key Comment
o Details

• Diamics, Inc.
o Key Comment
o Details

• Digene Corporation
o Key Comment
o Details

• eXagen Diagnostics, Inc.
o Key Comment
o Details

• HistoRx, Inc.

o Key Comment
o Details

• Ikonisys Inc.
o Key Comment
o Details

• Immunicon Corporation
o Key Comment
o Details

• InterGenetics, Inc.
o Key Comment
o Details

• MDS/Molecular Devices Corporation
o Key Comment
o Details

• MonoGen
o Key Comment
o Details

• mtm laboratories AG
o Key Comment
o Details

• Pathwork Diagnostics (formerly Predicant Biosciences)
o Key Comment
o Details

• Perceptronix Medical Inc.
o Key Comments
o Details

• Rational Therapeutics
o Key Comments
o Details

• Tripath Imaging, Inc.
o Key Comments
o Details

• Ventana Medical Systems. Inc.
o Key Comment
o Details

• Veridex, LLC
o Key Comment
o Details

• Vision BioSystems Ltd/Danaher Corp.
o Key Comment
o Details

Table of Exhibits
CHAPTER ONE: Executive Summary

• Figure 1-1: World In Vitro Diagnostics Market 2007-2012 ($millions)
• Table 1-2: Worldwide In Vitro Diagnostic Reagent Sales by Country/Region
2007-2012
• Figure 1-2: Regional Market Share of In Vitro Diagnostics Market, 2007 (North
America, EU, Japan, Latin America, Eastern Europe, India, China, ROW)
• Table 1-3: Top Tier IVD Companies, 2007 (Company, Country)
• Figure 1-3 Share of Top Tier Companies, 2007 vs. 2005
• Table 1-1: Exchange Rate Fluctuations, 2003-2007

CHAPTER TWO: Introduction

• Figure 2-1: Worldwide IVD Market Share by Segment
• Table 2-1: Worldwide In Vitro Diagnostic Sales by Product Market 2007-2012, $
million
• Table 2-2: Selected Diagnostics Industry Acquisitions, 2006-2007
• Table 2-3: Selected Diagnostics Industry Distribution Agreements 2006-2007
• Table 2-4: Selected Diagnostics Industry Collaborations and Licensing
Agreements, 2006-2007
• Table 2-5: Revenues of Selected IVD Companies, 2005-2007

CHAPTER THREE: OVERVIEW OF WORLD IVD MARKETS

• Table 3-1: Number of People Who Get Chronic Diseases Every Year Worldwide
by Disease
• Table 3-2: WHO Health Spending Statistics
• Figure 3-1: Health Expenditure as a Share of GDP, Developing Countries
• Figure 3-2 Health Expenditure per Capita: Private and Public
• Table 3-3: Worldwide In Vitro Diagnostics Sales by Country/Region 2007-2012
• Table 3-4: European Union IVD Sales by Country 2006
• Figure 3-3: Chinese Market for IVD Reagents 2007-2012
• Figure 3-4: Indian Market for IVD Reagents 2007-2012

CHAPTER FIVE: Point-of-Care Tests

• Table 5-1: POC Sales by Test Category, worldwide 2007-2012
• Table 5-2: World Glucose Monitoring Sales, by Company, 2005 - 2007
• Table 5-3: Selected Blood Glucose Test Devices Innovations, 2006-2007
• Table 5-4: Selected Blood Glucose Test Devices Innovations, 2006-2007

CHAPTER SIX: THE CORE LAB

• Table 6-1: Clinical Chemistry/Immunoassay Sales, 2007-2012

• Table 6-2: Chemistry/Immunochemistry Sales of Top Five Manufacturers, 2003-
2005
• Table 6-3: Selected Workstation Innovations, 2006-2007
• Table 6-4: Worldwide Clinical Chemistry Sales by Test Category 2007-2012
(General Chem, Blood Gases, Urinalysis, Critical Care, POC)
• Figure 6-1: Worldwide Clinical Chemistry Sales by Test Category (General
Chem, Blood Gases, Urinalysis, Critical Care, POC)
• Table 6-5: Selected Small Lab Workstations, 2006-2007 (Company, Location,
Details, Status)

CHAPTER SEVEN: IMMUNOASSAYS

• Table 7-1: Selected New Immunoassay Platforms, 2007
• Table 7-2: Selected Small Footprint Immunoassay Systems
• Table 7-3: Worldwide Lab-Based Immunoassay Sales by Analyte Type 2007-
2012 (ID, Tumor Markers, Cardiac Markers, Diabetes/HbA1c, Thyroid, Proteins,
Autoimmune, Anemia, Therapeutic Drugs, Fertility, Allergy, Drugs of Abuse)
• Table 7-4: Revenue History of Leading Immunoassay Vendors, $ million 2005-
2007
• Table 7-5: Selected Tumor Marker Innovations, 2006-2007
• Table 7-6: Selected Cardiac Marker Innovations, 2006-2007
• Table 7-7: Selected Autoimmune Immunoassay Innovations, 2006-2007
• Table 7-8: Selected Sepsis Marker Innovations, 2006-2007
• Table 7-9: Selected Immunoassay Innovations, 2006-2007
• Table 7-10: Regional Breakdown of POC Immunoassay Market
• Figure 7-1 Regional Breakdown of POC Immunoassay Market
• Figure 7-2: Growth Rate of Immunoassays (All Immunoassays, POC OTC
Immunoassays and Professional POC)
• Table 7-10: POC OTC Immunoassay Test Sales by Test Category 2007-2012
(Pregnancy/Ovulation, Fecal Occult Blood, Drugs of Abuse, Cholesterol)
• Table 7-11: Selected OTC Test Devices, 2007
• Table 7-12: Professional POC Testing 2005-2010 (Pregnancy, Cardiac Markers,
Cholesterol/Lipids, HbA1, Fecal occult blood, Cancer Markers, Drugs of Abuse,
Other)
• Table 7-13: Selected Professional POC Tests on the Market and in
Development, 2006-2007

CHAPTER EIGHT: Molecular Assays

• Table 8-1: Selected Molecular Test Innovations, 2006/07
• Table 8-2: Selected Nucleic Acid Testing Platforms, 2006-2007
• Table 8-3: Selected Molecular Test Services, 2007
• Table 8-4: Worldwide Molecular Test Sales by Type, $million 2007-2012
• Table 8-5: Molecular Test Revenues of Selected IVD Vendors, 2005-2007
• Table 8-6: Selected Molecular Sample Preparation Products
• Table 8-7: Worldwide Molecular Test Sales, 2005-2010 (Sales in millions)

• Table 8-8: Most Frequently Requested Genetic Tests

CHAPTER NINE: Hematology

• Table 9-1: Selected New Hematology Analyzer Tests 1990s - 2007
• Table 9-2: Selected New Hematology Research Projects
• Figure 9-1: Estimated Market for Manual and Automated Sed Rates 2007-2012
• Table 9-3: Selected Automated ESR Systems, 2007
• Figure 9-2: Estimated Share of Hematology Market by Setting (Central vs
Decentralized) 2007
• Table 9-4: Selected POC Hematology Systems, 2007
• Figure 9-3: Estimated Distribution of Hemoglobin Testing Volume by Region
(U.S., Europe, ROW)
• Table 9-5: Revenue History of the Major Hematology Vendors by Company
2001-2007
• Figure 9-4: Market Share of Hematology Vendors 2007
• Figure 9-5: World Market for Hematology 2007-2012
• Figure 9-6: Estimated Distribution of Hematology Revenues by Region (U.S.,
Europe, Japan, ROW) 2007
• Table 9-6: Selected Hematology Innovations (Company, Location, Segment,
Details, Market Status) 2006-2007

CHAPTER TEN: Coagulation

• Table 10-1: Worldwide Coagulation Sales by Segment 2007-2012
• Figure 10-1: Regional Share of Coagulation Market, 2007
• Figure 10-2: Lab-Based Coagulation Testing 2007-2012
• Table 10-2: Selected Coagulation Automation Innovations
• Figure 10-3: Growth Rate in Coagulation Testing Segments (Genetic Markers
compared to Lab-Based, POC Self Test, and POC Professional)
• Table 10-3: Selected New Warfarin Sensitivity Tests, 2006-2007 (Company,
Location, Test, Status)
• Figure 10-4 Decentralized (POC) Coagulation Testing, Professional: 2007 and
2012 ($millions)
• Figure 10-5: Coagulation POC Testing by Region (US, Europe, ROW)
• Table 10-4: CLIA Waived PT Devices
• Figure 10-6: Decentralized (POC) Coagulation Testing, Over the Counter: 2007
and 2012
• Table 10-5: Top Coagulation Company Revenues 2005 - 2007
• Table 10-6: Selected Coagulation Test Innovations 2006-2007

chapter eleven: Microbiology and Virology

• Table 11-1: Percent of Staph infections Among U.S. Intensive Care Patients
That Are Infected with MRSA
• Table 11-2: CLIA waved Tests for HIV Market

• Table 11-3: Selected HIV Test Innovation, 2007
• Table 11-4: PCR, FISH, Flow and Cell Imaging Systems for Bacteria / Virus
Detection, 2007 and 2012 ($million)
• Table 11-5: Worldwide Microbiology/Virology Sales by Type 2007-2012
• Table 11-4: Selected Chromogenic Growth Media
• Table 11-6: Revenue of Selected ID/AST Product Companies, 2007
• Table 11-7: Selected Microbiology/Virology Innovations, 2006-2007 (Company,
Location, Details, Status)
• Table 11-8: Selected Immunoassays for Sepsis (Company, Location, Details,
Status)
• Table 11-9: Selected Syphilis Immunoassays, 2007
• Table 11-10: Selected Infectious Disease Immunoassay Innovations, 2006-2007
• Table 11-11: Selected POC Tests for Infectious Diseases, 2006-2007
• Figure 11-1: Molecular Tests vs. Traditional Lab-Based Immunoassays 2005-
2012 ($millions)
• Table 11-12: Molecular Test Sales, Infectious Diseases by Type (HIV, Hepatits,
GC/Chlamydia, Organism ID, MRSA et. al, Mycobacteria, TB, Respiratory,
Others), 2007-2012 ($ Millions)
• Figure 11-2: Molecular Test Sales, Infectious Diseases by Type (HIV, Hepatits,
GC/Chlamydia, Organism ID, MRSA et. al, Mycobacteria, TB, Respiratory,
Others), 2007-2012
• Figure 11-3 Molecular Testing Emerging Infectious Disease vs. First Wave
• Table 11-13: Selected Infectious Disease Molecular Test Innovations, 2006-2007

CHAPTER TWELVE: Blood Banking Services

• Table 12-1: Selected Blood Treatment Systems, 2007
• Table 12-2: Worldwide Blood Bank Sales, 2007-2012 (ABO Grouping,
Immunoassay Screen, NAT Screen)
• Table 12-2: Worldwide Blood Bank Sales, 2007 and 2012 ($ millions)
• Figure 12-1: ABO Grouping Revenues by Region (North America, EU, Japan,
ROW)
• Table 12-3: Selected Blood Grouping Innovations, 2006-2007
• Table 12-4: Selected Blood Screen Immunoassay Innovations, 2006-2007
• Table 12-5: Selected Blood Bank Innovations, 2006-2007

chapter thirteen: Histology and Cytology

• Table 13-1: Selected IVD Cancer Markers
• Table 13-2: Selected Microscopy and Image Analysis Product Companies
• Figure 13-1: The Future of Pap Smear Testing, 2005 and 2012
• Table 13-3: Selected Advanced HPV Tests, 2006-2007
• Table 13-4: Worldwide Histology/Cytology Sales by Type 2007-2012 ($million)
• Figure 13-2: Worldwide Histology/Cytology Sales by Type 2007-2012 ($million)
• Table 13-5: Worldwide Flow Cytometry Sales 2007-2012 ($million)
• Table 13-6:Worldwide CTCs and Tissue Microarray Sales 2007-2012

• Table 13-7: Selected Vendors of Traditional Histology Stains
• Table 13-8: Revenues of the Major Automated Histology Companies $ million,
2003-2007
• Figure 13-3: Revenues of the Major Automated Histology Companies, 2003-2007
($millions)
• Table 13-9: Selected Pap Test Entrants, 2006-2007
• Figure 13-4 in situ Hybridization Market, 2007 and 2012
• Table 13-10: Selected IHC and ISH Reagent Companies
• Table 13-11: Selected molecular HPV tests, 2006-2007
• Table 13-12: Revenue History of the Cytometry Imaging Market, 2006 ($ million)
• Table 13-13: Selected Histology/Cytology Innovations, 2005
• Table 13-14: Revenue History of Flow Cytometry by Company, 2005-2007
• Figure 13-5: Market Share of Flow Cytometry by Company, 2005 and 2007

Available immediately for Online Download at
http://www.marketresearch.com/product/display.asp?productid=1430266

US: 800.298.5699

UK +44.207.256.3920

Int'l: +1.240.747.3093

Fax: 240.747.3004

Worldwide Market for In Vitro Diagnostic (IVD) Tests, 6th Edition [with 2009 economy preface], The

More Related Content

What's hot (17)

Similar to Worldwide Market for In Vitro Diagnostic (IVD) Tests, 6th Edition [with 2009 economy preface], The (20)

More from MarketResearch.com (20)

Worldwide Market for In Vitro Diagnostic (IVD) Tests, 6th Edition [with 2009 economy preface], The